Oncocyte is a molecular diagnostics company focused on developing and commercializing proprietary tests, laboratory-developed tests, to serve unmet medical needs across the cancer care continuum. Co. is developing DetermaRx, which is a predictive molecular test for early stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to help identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer. Co. has expanded its portfolio to include a gene expression-based test called DetermaIO, which is being developed to identify patients most likely to respond to immunotherapy drugs. The OCX stock yearly return is shown above.
The yearly return on the OCX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OCX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|